Brief: Oncternal Therapeutics Announces First Patient Dosed In Phase 1/2 Study Of Dual-Action AR Inhibitor
05/10/2023 21:38
Oct 5 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE
1/2 STUDY OF DUAL-ACTION AR INHIBITOR, ONCT-534, IN PATIENTS
WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
* ONCTERNAL THERAPEUTICS INC: WE EXPECT TO REPORT INITIAL
CLINICAL
DATA IN FIRST HALF OF 2024
* ONCTERNAL THERAPEUTICS INC - WILL BE ENROLLING PATIENTS IN
SITES
ACROSS U.S. OVER COMING WEEKS, AND IN UNITED KINGDOM IN EARLY
2024
Source text for Eikon: ID:nGNX99PSN7
Further company coverage: ONCT.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;